NF1 affects around 1.7 million people worldwide, with about 70% being adults ... before AZ and its partner Merck were able to ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Merck published phase 3 data on Tuesday. Investigators in China, Europe and North America randomized 94 people with TGCT to ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...

AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from ... progressive genetic condition affecting an estimated 1.7 million people worldwide, approximately 70% ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition and likely see sales slide noticeably. There aren't any obvious ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

data-text="Merck Announces Emerging Biotech Grant Program Winners" data-link=" Announces Emerging Biotech Grant Program ...

MERCK lowered the top end of its full-year sales guidance after demand for its HPV vaccine fell for a second straight quarter ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...